Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28575163 | 0.83 | KAT2B (0.40) | KAT2BMCL1 | |
| SCHEMBL28312340 | 0.77 | KAT2B (0.47) | KAT2BALDH1A1MCL1 | |
| SCHEMBL29849065 | 0.72 | KAT2B (0.41) | KAT2BALDH1A1MCL1 | |
| SCHEMBL17553821 | 0.72 | KAT2B (0.45) | KAT2BMCL1 | |
| SCHEMBL14911695 | 0.72 | IDO1 (0.45) | KAT2B | |
| SCHEMBL19743373 | 0.72 | KAT2B (0.41) | KAT2BALDH1A1MCL1 | |
| SCHEMBL11254980 | 0.72 | ALDH1A1 (0.38) | ALDH1A1HSD17B10TDP1TRPV4 | |
| SCHEMBL10641975 | 0.71 | ALDH1A1 (0.41) | ALDH1A1HSD17B10TDP1TRPV4 | |
| SCHEMBL29800774 | 0.71 | CTSB (0.52) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL1073769 | 0.71 | CTSB (0.52) | ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751844-B2 | Precursor compound connected to solid support for manufacturing 18F radiopharmaceutical, method for manufacturing same, and application thereof | FUTURECHEM CO., LTD. (KR) | 2017-09-05 | — | — | US | disclosed |
| US-9751844-B2 | Precursor compound connected to solid support for manufacturing 18F radiopharmaceutical, method for manufacturing same, and application thereof | FUTURECHEM CO., LTD. (KR) | 2017-09-05 | — | — | US | disclosed |
| US-20140011961-A1 | PRECURSOR COMPOUND CONNECTED TO SOLID SUPPORT FOR MANUFACTURING 18F RADIOPHARMACEUTICAL, METHOD FOR MANUFACTURING SAME, AND APPLICATION THEREOF | FUTURECHEM CO., LTD. (KR) | 2014-01-09 | — | — | US | disclosed |
| US-20140011961-A1 | PRECURSOR COMPOUND CONNECTED TO SOLID SUPPORT FOR MANUFACTURING 18F RADIOPHARMACEUTICAL, METHOD FOR MANUFACTURING SAME, AND APPLICATION THEREOF | FUTURECHEM CO., LTD. (KR) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011961-A1 | PRECURSOR COMPOUND CONNECTED TO SOLID SUPPORT FOR MANUFACTURING 18F RADIOPHARMACEUTICAL, METHOD FOR MANUFACTURING SAME, AND APPLICATION THEREOF | PFAS, RFT1, AFF1 | KAT2B 1184/4885ALDH1A1 1861/4885HSD17B10 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.